BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18704591)

  • 21. Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.
    Lee SJ; Kang HY; Kim SY; Chung JH; Oh SJ; Ryu JS; Kim SB; Kang JS; Park SK; Kim HM; Kim MH; Moon DH
    Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1436-48. PubMed ID: 21484374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
    Waldherr C; Mellinghoff IK; Tran C; Halpern BS; Rozengurt N; Safaei A; Weber WA; Stout D; Satyamurthy N; Barrio J; Phelps ME; Silverman DH; Sawyers CL; Czernin J
    J Nucl Med; 2005 Jan; 46(1):114-20. PubMed ID: 15632041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FLT-PET imaging of radiation responses in murine tumors.
    Pan MH; Huang SC; Liao YP; Schaue D; Wang CC; Stout DB; Barrio JR; McBride WH
    Mol Imaging Biol; 2008; 10(6):325-34. PubMed ID: 18670825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.
    Brepoels L; Stroobants S; Verhoef G; De Groot T; Mortelmans L; De Wolf-Peeters C
    J Nucl Med; 2009 Jul; 50(7):1102-9. PubMed ID: 19525456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
    Leyton J; Alao JP; Da Costa M; Stavropoulou AV; Latigo JR; Perumal M; Pillai R; He Q; Atadja P; Lam EW; Workman P; Vigushin DM; Aboagye EO
    Cancer Res; 2006 Aug; 66(15):7621-9. PubMed ID: 16885362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
    Ullrich RT; Zander T; Neumaier B; Koker M; Shimamura T; Waerzeggers Y; Borgman CL; Tawadros S; Li H; Sos ML; Backes H; Shapiro GI; Wolf J; Jacobs AH; Thomas RK; Winkeler A
    PLoS One; 2008; 3(12):e3908. PubMed ID: 19079597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice.
    Sugiyama M; Sakahara H; Sato K; Harada N; Fukumoto D; Kakiuchi T; Hirano T; Kohno E; Tsukada H
    J Nucl Med; 2004 Oct; 45(10):1754-8. PubMed ID: 15471845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of 3'-deoxy-3'-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors.
    Yang YJ; Ryu JS; Kim SY; Oh SJ; Im KC; Lee H; Lee SW; Cho KJ; Cheon GJ; Moon DH
    Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):412-9. PubMed ID: 16404598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular imaging of proliferation in malignant lymphoma.
    Buck AK; Bommer M; Stilgenbauer S; Juweid M; Glatting G; Schirrmeister H; Mattfeldt T; Tepsic D; Bunjes D; Mottaghy FM; Krause BJ; Neumaier B; Döhner H; Möller P; Reske SN
    Cancer Res; 2006 Nov; 66(22):11055-61. PubMed ID: 17108145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Use of 11F-fluorothymidine positron emission tomography in brain tumor].
    Kawai N; Kagawa M; Miyake K; Nishiyama Y; Yamamoto Y; Shiraishi H; Ichikawa T; Tamiya T
    No Shinkei Geka; 2009 Jul; 37(7):657-64. PubMed ID: 19621774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells.
    Zhang CC; Yan Z; Li W; Kuszpit K; Painter CL; Zhang Q; Lappin PB; Nichols T; Lira ME; Affolter T; Fahey NR; Cullinane C; Spilker M; Zasadny K; O'Brien P; Buckman D; Wong A; Christensen JG
    Clin Cancer Res; 2012 Mar; 18(5):1303-12. PubMed ID: 22170262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
    Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
    Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
    Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
    Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3'-Deoxy-3'-[(18)F]fluorothymidine (FLT) uptake in breast cancer cells as a measure of proliferation after doxorubicin and docetaxel treatment.
    Dittmann H; Jusufoska A; Dohmen BM; Smyczek-Gargya B; Fersis N; Pritzkow M; Kehlbach R; Vonthein R; Machulla HJ; Bares R
    Nucl Med Biol; 2009 Feb; 36(2):163-9. PubMed ID: 19217528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorine-18-Labeled Thymidine Positron Emission Tomography (FLT-PET) as an Index of Cell Proliferation after Pharmacological Ascorbate-Based Therapy.
    Cieslak JA; Sibenaller ZA; Walsh SA; Ponto LL; Du J; Sunderland JJ; Cullen JJ
    Radiat Res; 2016 Jan; 185(1):31-8. PubMed ID: 26720803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.
    McKinley ET; Ayers GD; Smith RA; Saleh SA; Zhao P; Washington MK; Coffey RJ; Manning HC
    PLoS One; 2013; 8(3):e58938. PubMed ID: 23554961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR Imaging.
    Schelhaas S; Wachsmuth L; Viel T; Honess DJ; Heinzmann K; Smith DM; Hermann S; Wagner S; Kuhlmann MT; Müller-Tidow C; Kopka K; Schober O; Schäfers M; Schneider R; Aboagye EO; Griffiths J; Faber C; Jacobs AH
    J Nucl Med; 2014 Jun; 55(6):983-8. PubMed ID: 24777288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
    Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
    Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.
    Vesselle H; Grierson J; Muzi M; Pugsley JM; Schmidt RA; Rabinowitz P; Peterson LM; Vallières E; Wood DE
    Clin Cancer Res; 2002 Nov; 8(11):3315-23. PubMed ID: 12429617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.